TNFRSF17 and cancer: Since more and more patients with RRMM are exposed to several lines of therapy, including CD38- and B-cell maturating antigen (BCMA)-targeted therapies (antibody and plasma cell treatments that help the body’s immune system to kill cancer cells) and will often relapse and become refractory to these therapies, it is important to identify effective treatment options in this setting.